Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
$93.28
+0.3%
$93.73
$87.95
$124.43
$1.74B0.89191,955 shs222,283 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
$29.36
$4.30
$31.70
$497.21MN/AN/AN/A
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
$15.31
+2.5%
$13.75
$11.41
$24.10
$2.00B1.961.19 million shs1.30 million shs
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$16.35
+1.3%
$15.96
$13.18
$34.29
$1.69B0.91.61 million shs1.25 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
+0.26%+1.28%-1.30%-7.96%-17.22%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%-0.02%-0.02%+2,935,499,900.00%
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
+2.48%+11.67%+6.99%+23.67%-33.92%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
+1.30%+3.61%-4.05%-42.99%+1.62%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
$93.28
+0.3%
$93.73
$87.95
$124.43
$1.74B0.89191,955 shs222,283 shs
Charming Medical Ltd stock logo
MCTA
Charming Medical
$29.36
$29.36
$4.30
$31.70
$497.21MN/AN/AN/A
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
$15.31
+2.5%
$13.75
$11.41
$24.10
$2.00B1.961.19 million shs1.30 million shs
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$16.35
+1.3%
$15.96
$13.18
$34.29
$1.69B0.91.61 million shs1.25 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
+0.26%+1.28%-1.30%-7.96%-17.22%
Charming Medical Ltd stock logo
MCTA
Charming Medical
0.00%0.00%-0.02%-0.02%+2,935,499,900.00%
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
+2.48%+11.67%+6.99%+23.67%-33.92%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
+1.30%+3.61%-4.05%-42.99%+1.62%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
2.70
Moderate Buy$131.0040.44% Upside
Charming Medical Ltd stock logo
MCTA
Charming Medical
1.00
SellN/AN/A
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
2.75
Moderate Buy$22.1844.88% Upside
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
2.79
Moderate Buy$36.14121.06% Upside

Current Analyst Ratings Breakdown

Latest MCTA, SGRY, ADUS, and VRDN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/4/2026
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
UpgradeHoldStrong-Buy
5/26/2026
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
Reiterated RatingSell (E+)
5/22/2026
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
DowngradeHold (C)Hold (C-)
5/18/2026
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
Reiterated RatingMarket Outperform$142.00
5/15/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Set Price Target$26.00
5/15/2026
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
Lower Price TargetUnderweight$102.00 ➝ $92.00
5/13/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Set Price Target$39.00
5/6/2026
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
Reiterated RatingBuy$17.00
5/6/2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
Boost Price TargetOutperform$30.00 ➝ $34.00
5/6/2026
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
Lower Price TargetMarket Outperform$150.00 ➝ $142.00
5/6/2026
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
UpgradeStrong SellHold
(Data available from 6/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
$1.42B1.22$6.50 per share14.36$58.72 per share1.59
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/A
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
$3.31B0.61$1.71 per share8.97$24.21 per share0.63
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
$70.85M23.79N/AN/A$6.18 per share2.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
$95.91M$5.4117.2413.821.286.89%9.80%7.34%8/3/2026 (Estimated)
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
-$77.90M-$0.60N/A47.845.90-2.28%1.04%0.41%8/4/2026 (Estimated)
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$342.60M-$3.32N/AN/AN/A-490.31%-80.19%-48.84%8/5/2026 (Estimated)

Latest MCTA, SGRY, ADUS, and VRDN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/5/2026Q1 2026
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
-$0.15-$0.03+$0.12-$0.28$797.69 million$810.90 million
5/5/2026Q1 2026
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
-$1.06-$0.90+$0.16-$0.90$0.04 million$0.14 million
5/4/2026Q1 2026
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
$1.52$1.62+$0.10$1.36$366.41 million$363.50 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
N/AN/AN/AN/AN/A
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/AN/AN/A
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
N/AN/AN/AN/AN/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
0.08
1.83
1.83
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/AN/AN/A
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
1.17
1.86
1.69
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
0.10
15.15
15.15

Institutional Ownership

CompanyInstitutional Ownership
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
95.35%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
N/A
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
4.10%
Charming Medical Ltd stock logo
MCTA
Charming Medical
N/A
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
2.00%
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
2.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Addus HomeCare Corporation stock logo
ADUS
Addus HomeCare
50,65918.67 million17.90 millionOptionable
Charming Medical Ltd stock logo
MCTA
Charming Medical
4916.94 millionN/AN/A
Surgery Partners, Inc. stock logo
SGRY
Surgery Partners
16,000130.79 million128.17 millionOptionable
Viridian Therapeutics, Inc. stock logo
VRDN
Viridian Therapeutics
50103.07 million100.60 millionOptionable

Recent News About These Companies

Viridian Therapeutics Raises $359 Million in Offerings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Addus HomeCare stock logo

Addus HomeCare NASDAQ:ADUS

$93.28 +0.24 (+0.26%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$93.35 +0.07 (+0.08%)
As of 06/12/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.

Charming Medical stock logo

Charming Medical NASDAQ:MCTA

$29.36 0.00 (0.00%)
As of 06/12/2026

We are a Hong Kong-based provider of Traditional Chinese Medicine (TCM)-inspired therapies and products. We offer a wide range of beauty, wellness, and postpartum services and products rooted and influenced by the principles and practices of TCM, such as the use of herbal ingredients, acupuncture techniques, Tuina massage, and dietary guidance. Operating under the Beauty Lab Group (“Beauty Lab”) brand, our Operating Subsidiaries in Hong Kong offer a wide range of TCM-inspired beauty, wellness, and postpartum therapies and products through our four wellness centers in Hong Kong. Our services are designed to meet diverse health improvement needs, including alleviating premenstrual syndrome, menstrual irregularities, dysmenorrhea, leukorrhea, pelvic inflammatory disease, menopausal care, breast health, and other common women’s health conditions. We believe that our TCM-inspired herbal therapies can help balance the female endocrine system and improve women’s constitution and overall health. Additionally, the Operating Subsidiaries offer TCM-inspired therapies tailored to men. We offer a wide range of beauty, wellness, and postpartum services for women with a focus on utilizing TCM approaches in addressing women’s health issues. Our beauty, wellness, and postpartum services include but are not limited to womb-warming therapy, BTS (Beauty, Tailor-made, Slim) pelvic detox therapy, agarwood moxibustion therapy, TCM-inspired prenatal massage, and Indonesian traditional abdominal binding. In addition, under the “Beauty Lab” brand, we also offer supplements products, including (i) TCM-inspired supplements products, such as Beauty Lab home herbal uterine care patch, probiotic intimate wash, and Yin nourishing pill sets, designed to support uterine health, improve physical weakness, and balance endocrine functions for female customers; and (ii) beauty products, including ginseng soothing anti-allergy moisturizing wash, which provide comprehensive care for skin issues, and scalp health. Moreover, we also offer consultancy services to provide TCM-inspired therapy technical training and dietary therapy training to other well-established and reputable beauty salons, massage centers, and similar institutions. In March 2025, we launched a franchise model for our Beauty Lab brand, granting exclusive rights to independent third parties (the “Franchisees”) to operate branded beauty and wellness outlets. Franchisees are authorized to offer services such as scalp and hair care and women’s wellness services under the Beauty Lab brand. We derive franchise-related revenue mainly from initial franchise fees, royalty and promotional fees, brand management fees, training and administration fees. As of March 31, 2025 and as of the date of this prospectus, we had 1 and 3 franchisees, respectively. We generated revenue of $6,221,751 and $6,015,375, respectively, and achieved a net income of $1,199,085 and $821,743, respectively, for the years ended March 31, 2025 and 2024. We generated revenue primarily through the following: (i) beauty, wellness, and postpartum services; (ii) sales of products; (iii) consultancy services; and (iv) franchise activities. For the fiscal years ended March 31, 2025 and 2024, the revenue from beauty, wellness, and postpartum services amounted to $5,967,277 and $5,813,814, representing 96.0% and 96.6% of total revenue, respectively. The revenue from sales of products was $207,766 and $88,992 for the fiscal years ended March 31, 2025 and 2024, representing 3.2% and 1.5% of total revenue, respectively. The revenue from consultancy services was nil and $112,569 for the fiscal years ended March 31, 2025 and 2024, representing 0% and 1.9% of total revenue, respectively. The revenue from franchise activities was $46,708 and nil for the fiscal years ended March 31, 2025 and 2024, representing 0.8% and 0% of total revenue, respectively. Our principal executive office is located Hong Kong.

Surgery Partners stock logo

Surgery Partners NASDAQ:SGRY

$15.31 +0.37 (+2.48%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$15.60 +0.29 (+1.86%)
As of 06/12/2026 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

Viridian Therapeutics stock logo

Viridian Therapeutics NASDAQ:VRDN

$16.35 +0.21 (+1.30%)
Closing price 06/12/2026 04:00 PM Eastern
Extended Trading
$16.38 +0.03 (+0.16%)
As of 06/12/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.